Xuedan Han, Jialei Liu, Yidong Zhang, Eric Tse, Qiyi Yu, Yu Lu, Yi Ma, Lufeng Zheng
{"title":"通过安罗替尼介导的细胞外基质和RhoA/ROCK信号通路调节提高抗肿瘤药物的肿瘤靶向性","authors":"Xuedan Han, Jialei Liu, Yidong Zhang, Eric Tse, Qiyi Yu, Yu Lu, Yi Ma, Lufeng Zheng","doi":"10.1016/j.jpha.2024.100984","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":94338,"journal":{"name":"Journal of pharmaceutical analysis","volume":"693 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway\",\"authors\":\"Xuedan Han, Jialei Liu, Yidong Zhang, Eric Tse, Qiyi Yu, Yu Lu, Yi Ma, Lufeng Zheng\",\"doi\":\"10.1016/j.jpha.2024.100984\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":94338,\"journal\":{\"name\":\"Journal of pharmaceutical analysis\",\"volume\":\"693 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pharmaceutical analysis\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jpha.2024.100984\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical analysis","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1016/j.jpha.2024.100984","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway